Effect of tangeretin on ovalbumin-provoked allergic respiratory asthma in Swiss albino mice
Purpose: To evaluate the effect of tangeretin on ovalbumin (OVA)-induced allergic respiratory asthma in Swiss albino mice.
Methods: Mice were injected intraperitoneally with 50 μg OVA dissolved in water and 1 mg of aluminium hydroxide (alum) on the first day, and on day 12. On days 22, 26 and 30, the mice were exposed to 1 % OVA for 30 min. Mice in the asthma control group received saline via the same route. Tangeretin (50 or 100 mg/kg body weight) was given orally from day 1 to day 30. On the day of sensitization and challenge, tangeretin (50 or 100 mg/kg body weight) was injected 30 min prior to the treatment. Bronchial function, degree of inflammation, broncho-alveolar lavage fluid (BALF), levels of IL-4, IL-5, IL-13 and IFN-γ in BALF, serum total IgE, OVA-specific IgE, IgG1 and IgG2a, as well as histopathology of lungs were determined.
Results: Tangeretin administration led to significant reduction in airway sensitivity, and significant decreases in leukocyte, macrophage, and eosinophil counts (p < 0.05). It also brought about significant decreases in the levels of the pro-inflammatory cytokines (IL-4, IL-5 and IL-13) in both BALF and serum (p < 0.05). In addition, tangeretin reversed the OVA-induced histopathological anomalies in the lungs.
Conclusion: These results demonstrate that tangeritin exerts protective effects against OVA-induced allergic respiratory asthma in Swiss albino mice, and that the drug can potentially be developed for the management of allergic asthma.
Keywords: Allergic asthma, Inflammation, Cytokines, Ovalbumin, Tangeretin
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.